CervoMed Inc. Logo

CervoMed Inc.

Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.

CRVO | US

Overview

Corporate Details

ISIN(s):
US2537484048 (+1 more)
LEI:
Country:
United States of America
Address:
20 PARK PLAZA, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related, neurodegenerative diseases. The company advances central nervous system (CNS) therapeutics by targeting synaptic dysfunction, the reversible aspect of the neurodegenerative process, in the early stages of disease. Its lead investigational product is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with dementia with Lewy bodies (DLB).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:08
Regulatory News Service
8-K - CervoMed Inc. (0001053691) (Filer)
English 80.6 KB

Automate Your Workflow. Get a real-time feed of all CervoMed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CervoMed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CervoMed Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea
188260
Sanofi Logo
Global biopharma firm researching, developing & marketing prescription medicines & vaccines.
France
SAN
SANTEN PHARMACEUTICAL CO.,LTD. Logo
A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.
Japan
4536
Santhera Pharmaceuticals Holding AG Logo
Develops innovative medicines for rare neuromuscular and mitochondrial disorders.
Switzerland
SANN
Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America
SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America
SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.